InternationalUSRemember you can easily switch between MIP US and MIP International at any time

MIP European Life Sciences Forum 2018

April 24, Le Méridien Piccadilly London


Overview

Register here

Registration is now open - confirm your place online

Free registration for IP in-house counsel, Patent/Trademark counsel/attorneys, IP managers, heads/directors of IP, patents and more


The MIP European Life Sciences Forum 2018 returns for its second year at the Le Méridien Piccadilly in London on 24th April. The life sciences industry is one of the most complex, contentious and rapidly developing fields, by attend you will participate in identifying key challenges faced by life sciences companies.

This year the programme addresses the major issues at hand and will encourage participation and debate on all of the pertinent topics such as: Doctrine of equivalents and the impact of the decision across your European portfolio; application of issues surrounding the use of Arrow declarations and; patent protection strategies involving divisionals.

Not only will you have the opportunity to learn about the most significant developments in the global patent landscape over the past year but you will have a fantastic opportunity to network with your peers over delightful coffee and lunch.



Download the brochure here



Who you will meet?

  • IP in-house counsel
  • Patent/Trade mark counsel/Attorneys
  • IP counsel and IP managers
  • VP/SVP Patents
  • General counsel
  • Corporate counsel
  • Private practice lawyers
  • Heads/Directors of IP, patents & Legal affairs



Benefit of attending:

  • Hear how you should be rethinking your European strategy in preparation for Brexit
  • Listen to essential case updates and considerations when enforcing second medical use claims
  • Discuss the application of the doctrine of equivalents and the impact on life sciences companies
  • Learn from companies on application of the issues surrounding Arrow declarations
  • Identify and overcome the challenges of enforcing your SPC’s
  • Learn best practice to manage the global threat caused by counterfeit drugs
  • Join analysis on the trends that are influencing litigation of biosimilars in EU, UK & US
  • Examine the implications of AI and how it is being used in the development of medicine



REGISTRATION & ENQUIRIES

Kevin Pragas
+44 (0) 207 779 8938
registrations@managingip.com


SPEAKING ENQUIRIES
Natalie Canter
+44 (0) 207 779 8730
natalie.canter@managingip.com


SPONSORSHIP ENQUIRIES
Melanie Petch
+44 (0) 207 779 8836
mpetch@euromoneyplc.com


Sponsors

Dechert

Gorodissky

GowlingWLG


profile

Managing IP

ManagingIP

ManagingIP profile

John Bochnovic, Executive Director of AIPPI, has resigned from the position (effective April 30, 2018) to return to… https://t.co/4dp8lsqg5Z

Feb 16 2018 04:19 ·  reply ·  retweet ·  favourite
ManagingIP profile

CAFC says 101 inquiry is a factual determination in “blockbuster” Berkheimer opinion https://t.co/wpYscoUhnY https://t.co/FPrkImTmGL

Feb 16 2018 03:13 ·  reply ·  retweet ·  favourite
ManagingIP profile

US falls to 12th in US Chamber patent ranking https://t.co/UP7AvAbZ4k Expect to hear this figure mentioned a lot at… https://t.co/gnWLDdISl2

Feb 15 2018 04:45 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null null null

null null null

February 2018

FRAND aid: Is the European Commission’s SEP guidance useful?

Both patent owners and implementers have welcomed the European Commission’s communication on standard essential patents. Does that mean it has successfully balanced competing interests or merely dodged the difficult questions? James Nurton investigates



Most read articles

Supplements